The incidence of hirsutism in women of reproductive age is 5-10%, and the most common cause is polycystic ovary syndrome (PCOS), which accounts for 72-82% of hirsutism, mainly due to sex hormones or over-sensitivity to androgens in the body. The main distribution areas of female hirsutism are upper lip, jaw, chest, lower abdomen, inner thighs, etc., which can affect their aesthetics in severe cases. When treating hirsutism, attention should be paid to identify various diseases with increased hormone levels, and special attention should be paid to exclude malignant tumors. The principle of treatment for female hirsutism is to correct sex hormone levels, slow down or stop hair growth, and improve the quality of life. Combination oral contraceptives containing 3rd generation progestins, and combination oral contraceptives containing anti-androgenic progestins are the first line of treatment for hirsutism. Combination oral contraceptives containing 3rd generation progestins with a progestin component with low androgenic activity. The effectiveness of combination oral contraceptives containing progestins with anti-androgenic activity is positive. Combination oral contraceptives containing 2nd generation progestins can be used in people prone to thrombosis to reduce the risk of blood clots. Treatment of hirsutism usually requires 6 months of anti-androgen medication to be effective, and foreign guidelines also recommend 1-2 years, as serum androgen levels can remain continuously suppressed for up to 2 years after long-term use of combination oral contraceptives is discontinued.